Syncom Formulations (India) Limited
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.
What Syncom files
- Others45
- Important15
- Updates9
- Board Meeting7
- Dividend/Bonus3
- Results1
Syncom Formulation's Managing Director, Mr. Vijay Shankarlal Bankda, has resigned, effective August 11, 2026. **Issue:** Resignation of a key leadership figure. **Company's Response/Mitigation:** The company states this is part of a deliberate leadership transition and succession planning process, aimed at ensuring stability, continuity, and a smooth handover to incoming leadership....
SYNCOMF announces its Whole-Time Director, Mr. Kedarmal Shankarlal Bankda, has resigned, effective 11th August, 2026. **Issue:** A key leadership change with the departure of a Whole-Time Director. **Possible Impact:** Investors might look for clarity on leadership stability and operational continuity. **Company's Response/Mitigation:** The company states the reasons are "timely succession...
Syncom Formulation (SYNCOMF) has announced the resignation of its Managing Director, Mr. Vijay Shankarlal Bankda. His resignation is effective from August 11. This creates a leadership vacuum, and investors will be keen to see the company's plan for succession and how it intends to maintain strategic direction. #SYNCOMF #LeadershipChange #InvestorAlert
SYNCOMF Update: Company announces its Chief Financial Officer, Mr. Rahul Vijay Bankda, has resigned, effective 11th August, 2026. This marks a key change in the company's financial leadership, which investors might note for future continuity. The company has made the necessary regulatory disclosure, but the filing does not provide details...
Syncom Formulation (India) Ltd. (NSE: SYNCOMF) announces Whole-Time Director Mr. Kedarmal Shankarlal Bankda has resigned, effective August 11, 2026. This leadership change could spark investor queries on company stability and future strategy. No reason for departure or succession plan has been disclosed.